WASHINGTON — An advisory panel has urged the Food and Drug Administration to loosen its restrictions on the controversial diabetes drug Avandia, which was nearly wiped from the market in recent years after reports linking it to several heart-related complications.
Published: January 21, 2013
Tags: diabetes, insulin, medical malpractice, medical transcription, Medusind, Precyse Solutions, punitive damages, Thomas Hospital, Top Ten Jury Verdicts, Top Ten Jury Verdicts of 2012
Sharron Juno died because of a typo.
A lifelong diabetic, Juno had her insulin dosage dictated by her doctor in Alabama but transcribed by an outsourced sub-contractor in India, who wrote “80” instead of “8.”
Drug maker Takeda failed to report bladder cancer and heart failure adverse events for its diabetes drug Actos, a whistleblower claims in a just-unsealed federal lawsuit.
A Nevada man and his wife are receiving $292,500 from Henderson police and the state of Nevada to settle a federal lawsuit stemming from a kicking and punching attack on the man during an October 2010 traffic stop.
GlaxoSmithKline has announced a tentative deal with the federal government under which the drug company would pay a record $3 billion to end an investigation into the marketing of Avandia for “off-label” uses.
AstraZeneca Plc has settled almost all lawsuits that claimed its antipsychotic drug Seroquel causes diabetes in some users for a total of $647 million.
The University of Iowa Hospitals and Clinics agreed to a $1.5 million settlement to end a lawsuit that claimed surgeons made a key mistake while giving a diabetic woman a kidney transplant, leaving her unable to work and dependent on insulin for life, according to records obtained by The Associated Press.
GlaxoSmithKline Plc, after setting aside more than $6 billion to help settle lawsuits over medicines including its Avandia diabetes drug, is poised to resolve 1,000 more cases, a lawyer for patients said.
GlaxoSmithKline has agreed to pay more than $250 million to resolve about 5,500 claims related to its diabetes drug Avandia, reports Bloomberg, citing information from two individuals close to the accords.